Angiotensin converting enzyme genotype influences the response to the angiotensin II receptor antagonist losartan in patients with hypertension

Hypertension Research

Volumn 27, Issue 3, 2004, Pages 137-140

  Nakamura, Yasuyuki ^a   Tamaki, Shinji ^a   Uchida, Yasukazu ^b   Ohmichi, Nobuyuki ^c   Yamaoka, Osamu ^c   Miyauchi, Nobuo ^d   Fukuhara, Takehisa ^a   Sayama, Harumi ^e   Yamada, Tetsuhiro ^a   Matsuo, Shinro ^a   Yamada, Yutaka ^f  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b Moriyama Municipal Hospital   (Japan)

^c Social Insurance Shiga Hospital   (Japan)

^d Shigaraki National Hospital   (Japan)

^e Hino Memorial Hospital   (Japan)

^f Vories Memorial Hospital   (Japan)

Author keywords

Angiotensin II receptor antagonist; Losartan; Tailored medicine

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; LOSARTAN;

ADULT; AGE; ALLELE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; GENOTYPE; HUMAN; HYPERTENSION; MALE; MULTIPLE REGRESSION; PREDICTION; PROSPECTIVE STUDY; SEX DIFFERENCE; SEX RATIO; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIASTOLE; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; PROSPECTIVE STUDIES; RECEPTORS, ANGIOTENSIN;

EID: 11144357531     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.27.137     Document Type: Article

References (22)

1. Agerholm-Larsen B, Nordestgaard BG, Tybjaerg-Hansen A: ACE gene polymorphism in cardiovascular disease: meta-analyses of small and large studies in whites. Arterioscler Thromb Vasc Biol 2000; 20: 484-492.
2. Tamaki S, Nakamura Y, Tsujita Y, et al: Polymorphism of the angiotensin converting enzyme gene and blood pressure in a Japanese general population (the Shigaraki Study). Hypertens Res 2002; 25: 843-848.
3. Gardemann A, Weiss T, Schwartz O, et al: Gene polymorphism but not catalytic activity of angiotensin I-converting enzyme is associated with coronary artery disease and myocardial infarction in low-risk patients. Circulation 1995; 92: 2796-2799.
4. Mattu RK, Needham EW, Galton DJ, Frangos E, Clark AJ, Caulfield M: A DNA variant at the angiotensin-converting enzyme gene locus associates with coronary artery disease in the Caerphilly Heart Study. Circulation 1995; 91: 270-274.
5. Cambien F, Costerousse O, Tiret L, et al: Plasma level and gene polymorphism of angiotensin-converting enzyme in relation to myocardial infarction. Circulation 1994; 90: 669-676.
6. Winkelmann BR, Nauck M, Klein B, et al: Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease. Ann Intern Med 1996; 125: 19-25.
7. Sugiyama T, Morita H, Kato N, Kurihara, Yamori Y, Yazaki Y: Lack of sex-specific effects on the association between angiotensin-converting enzyme gene polymorphism and hypertension in Japanese. Hypertens Res 1999; 22: 55-59.
8. Ohmichi N, Iwai N, Uchida Y, Shichiri G, Nakamura Y, Kinoshita M: Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype. Am J Hypertens 1997; 10: 951-955.
9. Katsuya T, Iwashima Y, Sugimoto K, et al: Effects of antihypertensive drugs and gene variants in the renin-angiotensin system. Hypertens Res 2001; 24: 463-467.
10. Iwai N, Ohmichi N, Nakamura Y, Kinoshita M: DD genotype of the angiotensin-converting enzyme gene is a risk factor for left ventricular hypertrophy. Circulation 1994; 90: 2622-2628.
11. Krege JH, Kim HS, Moyer JS, et al: Angiotensin-converting enzyme gene mutations, blood pressures, and cardiovascular homeostasis. Hypertension 1997; 29: 150-157.
12. Johnston CI, Jackson B, McGrath B, Matthews G, Arnolda L: Relationship of antihypertensive effect of enalapril to serum MK-422 levels and angiotensin converting enzyme inhibition. J Hypertens 1983; 1 (Suppl): 71-75.
13. Todd GP, Chadwick IG, Higgins KS, Yeo WW, Jackson PR, Ramsay LE: Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects. Br J Clin Pharmacol 1995; 39: 131-134.
14. Myerson SG, Montgomery HE, Whittingham M, et al: Left ventricular hypertrophy with exercise and ACE gene insertion/deletion polymorphism: a randomized controlled trial with losartan. Circulation 2001; 103: 226-230.
15. Andersen S, Tarnow L, Cambien F, et al: Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Kidney Int 2002; 62: 192-198.
16. Andersen S, Tarnow L, Cambien F, et al: Long-term renoprotective effects of losartan in diabetic nephropathy. Diabetes Care 2003; 26: 1501-1506.
17. Ereshefsky L: Antidepressant pharmacodynamics, pharmacokinetics, and drug interactions. Geriatrics 1998; 53(Suppl 4): S22-S33.
18. Jann MW, Cohen LJ: The influence of ethnicity and antidepressant pharmacogenetics in the treatment of depression. Drug Metab Drug Interact 2000; 16: 39-67.
19. Pillans PI: Increasing relevance of pharmacogenctics of drug metabolism in clinical practice. Intern Med J 2001; 31: 476-478.
20. Relling MV, Dervieux T: Pharmacogenetics and cancer therapy. Nat Rev Cancer 2001; 1: 99-108.
21. Higaki J, Baba S, Katsuya T, et al: Deletion allele of angiotensin-converting enzyme gene increases risk of essential hypertension in Japanese men: the Suita Study. Circulation 2000; 101: 2060-2065.
22. Zaman MM, Yoshiike N, Date C, et al: Angiotensin converting enzyme genetic polymorphism is not associated with hypertension in a cross-sectional sample of a Japanese population: the Shibata Study. J Hypertens 2001; 19: 47-53.